We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Dr. Durie's Blog: Life Extension? No, Let's Shoot for Permanent Remission
In the two weeks since we lost one of our most beloved patients, Mike Katz, our inability to cure myeloma has been staring us in the face. While the extended lives of myeloma patients is something to be celebrated, we need decisively better drugs to achieve our goal of permanent remission. How do we set the bar high enough to achieve these great outcomes?

Living Well with Myeloma: Sustainable Wellness – An Integrative Approach to Transform Your Mind, Body, and Spirit teleconference
The next Living Well With Myeloma Teleconference is Thursday, May 7, 2015. The subject is one that has been “in the news” and a hot topic in the medical world: Sustainable Wellness. Our Speaker for this topic is Dr. Matt Mumber and he has put together an excellent presentation that we feel will be beneficial to you and your group members.

In Loving Memory of Our Dear Friend Mike Katz, Long-Term IMF Board Member and Leading Patient Advocate
As you know, this past weekend the IMF lost a long-standing Board member and friend, Michael Katz. He routinely inspired patients to take charge of their myeloma and brought myeloma patient advocacy to the forefront. He was a colleague and friend to patients and physicians alike. IMF President Susie Novis recalls the many accomplishments and special spirit that made Mike a hero for myeloma patients everywhere. Read the story here. http://bit.ly/1OJVeCD

The International Myeloma Foundation Mourns the Passing of Board of Directors Member, Patient Champion, Michael S. Katz

This weekend the IMF lost a founding Board member who brought myeloma patient advocacy to the forefront. "Susie and I lost a dear and wonderful friend,” said IMF Chairman Dr. Brian Durie. “Mike Katz routinely inspired patients to take charge of their myeloma—to understand what is going on and get questions answered. He was a colleague and friend to patients and physicians alike. Mike, we will all miss you, we love you and will remember you always."

The Value of Annual PET/CT as a Screening Tool for Myeloma Patients
In last week’s blog, “How to Be Safer as You Live Longer,” IMF Chairman Brian Durie, MD cited the value of annual PET/CT as a screening tool to monitor low-level myeloma, detect hidden infection or an early second cancer. But what should a patient know when Medicare and supplemental insurance companies don’t cover the cost? In this week’s blog, Dr. Durie offers support for patients attempting to obtain reimbursement for these screenings. Click HERE to read.

Myeloma Patient Seminar in Italy Includes a Dash of Poetry
More than 100 people gathered in the town of Udine, Italy last week for a lively and informative myeloma patient event hosted by the Italian blood cancer patient group AIL. The organization is supported by a dedicated team of volunteers, according to IMF’s Director of Europe and the Middle East, Nadia Elkebir. Nadia delivered a well-received presentation about the IMF during the panel presentations in Udine and she reports on the many highlights of the event HERE.

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE.

Bristol-Myers Squibb Announces Opening of Expanded Access Program for Elotuzumab
Bristol-Myers Squibb (BMS) has opened an expanded access protocol for its monoclonal antibody elotuzumab in combination with Revlimid® and dexamethasone. Expanded access is a process regulated by the Food and Drug Administration (FDA) that allows manufacturers to provide investigational new drugs to patients with serious diseases or conditions who cannot participate in a clinical trial. ?While data from a large, phase III randomized trial comparing elotuzumab plus Rev/dex versus Rev/dex alone is eagerly anticipated, in the interim patients may now enroll at an available site for access to this new combination therapy. The first 5 of a planned 50-60 sites are now enrolling patients with myeloma that has relapsed after 1-3 prior treatments. For eligibility criteria and site information CLICK HERE.

How to Be Safer as You Live Longer: A Patient Checklist
Effective new therapies have extended the lives of many myeloma patients. But with that wonderful benefit comes the need to stay vigilant about disease and treatment side effects, as well as health challenges facing us all as we age. In his blog this week, IMF Chairman Dr. Brian Durie offers an awareness checklist for patients. To read CLICK HERE.

Calling All Nurses: Symposium on Nursing Implications Offered in Orlando
Nurses – so essential to optimal patient outcomes – are invited to attend the IMF’s Nurse Leadership Board’s symposium, “Case Studies in Myeloma: Nursing Implications of Evolving Treatment Paradigms.” The nurse’s roles as patient manager, advocate, and educator are integrated into this engaging 1.5 CNE learning opportunity to be held April 23 in Orlando, FL. To register, CLICK HERE.

previous     next      view all